A guide to economic evaluation: Methods for cost-effectiveness analysis of person-level data

Journal of Traumatic Stress

Volumn 19, Issue 6, 2006, Pages 787-797

  Hoch, Jeffrey S ^a,b,e   Smith, Mark W ^c,d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d STANFORD UNIVERSITY   (United States)

^e Centre for Research on Inner City Health   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; HEALTH CARE SYSTEM; HUMAN; INTERMETHOD COMPARISON; POSTTRAUMATIC STRESS DISORDER; PSYCHOTHERAPY; QUALITY ADJUSTED LIFE YEAR; COST BENEFIT ANALYSIS; DRUG THERAPY; ECONOMICS; HEALTH CARE COST; METHODOLOGY; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; REVIEW; STATISTICAL MODEL; STATISTICS;

COST-BENEFIT ANALYSIS; DRUG THERAPY; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMETRIC; MULTIVARIATE ANALYSIS; PSYCHOTHERAPY; QUALITY-ADJUSTED LIFE YEARS; REGRESSION ANALYSIS; STRESS DISORDERS, POST-TRAUMATIC;

EID: 33847789701     PISSN: 08949867     EISSN: 15736598     Source Type: Journal    
DOI: 10.1002/jts.20190     Document Type: Conference Paper

References (42)

1. Arnesen, T., & Trommald, M. (2004). Roughly right or precisely wrong? Systematic review of quality-of-life weights elicited with the time trade-off method. Journal of Health Services Research and Policy, 9, 43-50.
2. Baker, C. B., Johnsrud, M. T., Crismon, M. L., Rosenheck, R. A., & Woods, S. W. (2003). Quantitative analysis of sponsorship bias in economic studies of antidepressants. British Journal of Psychiatry, 183, 498-506.
3. Bala, M. V., & Zarkin, G. A. (2000). Are QALYs an appropriate measure for valuing morbidity in acute diseases? Health Economics, 9, 177-180.
4. Bell, C. M., Urbach, D. R., Ray, J. G., Bayoumi, A., Rosen, A. B., Greenberg, D., et al. (2006). Bias in published cost effectiveness studies: Systematic review. British Medical Journal, 332(7543), 699-703.
5. Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., et al. (1995). The development of a Clinician-Administered PTSD Scale. Journal of Traumatic Stress, 8, 75-90.
6. Chan, A. O., Medicine, M., Air, T. M., & McFarlane, A. C. (2003). Posttraumatic stress disorder and its impact on the economic and health costs of motor vehicle accidents in South Australia. Journal of Clinical Psychiatry, 64, 175-181.
7. Chisholm, D., Healey, A., & Knapp, M. (1997). QALYs and mental health care. Social Psychiatry and Psychiatric Epidemiology, 32(2), 68-75.
8. Cohen, H. E. (2004). Foreward. Red Book 2004.
9. Devlin, N., & Parkin, D. (2004). Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics, 13, 437-452.
10. Drummond, M. F. (2005). Methods for the economic evaluation of health care programmes (3rd ed.). New York: Oxford University Press.
11. Drummond, M. F., & Jefferson, T. O. (1996). Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. British Medical Journal, 313(7052), 275-283.
12. Drummond, M. F., Richardson, W. S., O'Brien, B. J., Levine, M., & Heyland, D. (1997). Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group. Journal of the American Medical Association, 277, 1552-1557.
13. Evers, S., Goossens, M., de Vet, H., van Tulder, M., & Ament, A. (2005). Criteria list for assessment of methodological quality of economic evaluations: Consensus on health economic criteria. International Journal of Technology Assessment and Health Care, 21, 240-245.
14. Fenton, W. S., Hoch, J. S., Herrell, J. M., Mosher, L., & Dixon, L. (2002). Cost and cost-effectiveness of hospital vs residential crisis care for patients who have serious mental illness. Archives of General Psychiatry, 59, 357-364.
15. Fenwick, E., & Byford, S. (2005). A guide to cost-effectiveness acceptability curves. British Journal of Psychiatry, 187, 106-108.
16. Fenwick, E., Marshall, D. A., Levy, A. R., & Nichol, G. (2006). Using and interpreting cost-effectiveness acceptability curves: An example using data from a trial of management strategies for atrial fibrillation. BMC Health Services Research, 6, 52.
17. Fenwick, E., O'Brien, B. J., & Briggs, A. (2004). Cost-effectiveness acceptability curves - Facts, fallacies and frequently asked questions. Health Economics, 13, 405-415.
18. George, B., Harris, A., & Mitchell, A. (2001). Cost-effectiveness analysis and the consistency of decision making: Evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics, 19, 1103-1109.
19. Gold, M. R., Siegel, J. E., Russell, L. B., & Weinstein, M. C. (1996). Cost-effectiveness in health and medicine. New York: Oxford University Press.
20. Hargreaves, W. A., Shumway, M., Hu, T. W., & Cuffel, B. (1998). Cost-outcome methods for mental health. San Diego: Academic Press.
21. Hirth, R. A., Chernew, M. E., Miller, E., Fendrick, A. M., & Weissert, W. G. (2000). Willingness to pay for a quality-adjusted life year: In search of a standard. Medical Decision Making, 20, 332-342.
22. Hoch, J. S. (2004). Cost-effectiveness lessons from disease-modifying drugs in the treatment of multiple sclerosis. Expert Review of Pharmacoeconomics & Outcomes Research, 4, 537-547.
23. Hoch, J. S., Briggs, A. H., & Willan, A. R. (2002). Something old, something new, something borrowed, something blue: A framework for the marriage of health econometrics and cost-effectiveness analysis. Health Economics, 11, 415-430.
24. Hoch, J. S., Rockx, M. A., & Krahn, A. (2006). Using the net benefit regression framework to construct cost-effectiveness acceptability curves: An example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope. BMC Health Services Research, 6, 68.
25. Hoff, R. A., & Rosenheck, R. A. (1998). Long-term patterns of service use and cost among patients with both psychiatric and substance abuse disorders. Medical Care, 36, 835-843.
26. Krabbe, P. F., Essink-Bot, M. L., & Bonsel, G. J. (1997). The comparability and reliability of five health-state valuation methods. Social Science and Medicine, 45, 1641-1652.
27. Lothgren, M., & Zethraeus, N. (2000). Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Economics, 9, 623-630.
28. Magruder, K. M., & Miller, N. E. (1999). Cost-effectiveness of psychotherapy: A guide for practitioners, researchers, and policymakers. New York: Oxford University Press.
29. McCrone, P., Knapp, M., & Cawkill, P. (2003). Posttraumatic stress disorder (PTSD) in the Armed Forces: Health economic considerations. Journal of Traumatic Stress, 16, 519-522.
30. Nicholson, S., Pauly, M. V., Polsky, D., Baase, C. M., Billotti, G. M., Ozminkowski, R. J., et al. (2005). How to present the business case for healthcare quality to employers. Applied Health Economics and Health Policy, 4, 209-218.
31. O'Brien, B. J., Heyland, D., Richardson, W. S., Levine, M., & Drummond, M. F. (1997). Users' guides to the medical literature: XIII. How to use an article on economic analysis of clinical practice: B. What are the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. Journal of the American Medical Association, 277, 1802-1806.
32. Shumway, M. (2003). Preference weights for cost-outcome analyses of schizophrenia treatments: Comparison of four stakeholder groups. Schizophrenia Bulletin, 29, 257-266.
33. Smith, M. W., & Joseph, G. J. (2003). Pharmacy data in the VA health care system. Medical Care Research and Review, 60(Suppl 3), 92S-123S.
34. Stinnett, A. A., & Mullahy, J. (1998). Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. Medical Decision Making, 18(Suppl 2), S68-S80.
35. Tambour, M., Zethraeus, N., & Johannesson, M. (1998). A note on confidence intervals in cost-effectiveness analysis. International Journal of Technology Assessment in Health Care, 14, 467-471.
36. Trueman, P., Drummond, M., & Hutton, J. (2001). Developing guidance for budget impact analysis. Pharmacoeconomics, 19, 609-621.
37. Ubel, P. A., Hirth, R. A., Chernew, M. E., & Fendrick, A. M. (2003). What is the price of life and why doesn't it increase at the rate of inflation? Archives of Internal Medicine, 163, 1637-1641.
38. van Etten, M. L., & Taylor, S. (1998). Comparative efficacy of treatments for posttraumatic stress disorder: A meta-analysis. Clinical Psychology & Psychotherapy, 5(3), 126-144.
39. van Hout, B. A., Al, M. J., Gordon, G. S., & Rutten, F. F. (1994). Costs, effects and C/E-ratios alongside a clinical trial. Health Economics, 3, 309-319.
40. Weathers, F. W., Keane, T. M., & Davidson, J. R. (2001). Clinician-Administered PTSD Scale: A review of the first ten years of research. Depression and Anxiety, 13, 132-156.
41. Weisbrod, B. A., Test, M. A., & Stein, L. I. (1980). Alternative to mental hospital treatment: II. Economic benefit-cost analysis. Archives of General Psychiatry, 37, 400-405.
42. Williams, A. (1992). Cost-effectiveness analysis: Is it ethical? Journal of Medical Ethics, 18, 7-11.